{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:06:24Z","timestamp":1789452384879,"version":"build-2803163510"},"reference-count":52,"publisher":"Jaypee Brothers Medical Publishing","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.59556\/japi.74.1694","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:57:55Z","timestamp":1789451875000},"page":"83-92","source":"Crossref","is-referenced-by-count":0,"title":["A Consensus Statement on the Role of Bisoprolol across the CV Continuum"],"prefix":"10.59556","volume":"74","author":[{"given":"Aditya","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayasagar","family":"Rao V","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadanand R","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit R","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadananda","family":"KS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B C","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumitra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PK","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Justin","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20260915055752_B1","first-page":"7\u2013","article-title":"\u03b2-blockers across the cardiovascular continuum: cardioprotection and cardioselectivity.","volume":"9:","author":"Pavasini","year":"2014;","journal-title":"Hot Top Cardiol"},{"key":"key20260915055752_B2","doi-asserted-by":"crossref","first-page":"100156.","DOI":"10.1016\/j.lansea.2023.100156","article-title":"The burgeoning cardiovascular disease epidemic in Indians\u2014perspectives on contextual factors and potential solutions.","volume":"12:","author":"Kalra","year":"2023;","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"key20260915055752_B3","doi-asserted-by":"crossref","first-page":"959285.","DOI":"10.3389\/fcvm.2022.959285","article-title":"Hypertension as a risk factor for atherosclerosis: cardiovascular risk assessment.","volume":"9:","author":"Poznyak","year":"2022;","journal-title":"Front Cardiovasc Med"},{"issue":"(25):","key":"key20260915055752_B4","doi-asserted-by":"crossref","first-page":"2850\u2013","DOI":"10.1161\/CIRCULATIONAHA.106.655688","article-title":"The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).","volume":"114","author":"Dzau","year":"2006;","journal-title":"Circulation"},{"key":"key20260915055752_B5","unstructured":"World Health Organization. (2026). Hypertension. [online] Available from: https:\/\/www.who.int\/india\/health-topics\/hypertension [Last accessed August, 2026]."},{"key":"key20260915055752_B6","doi-asserted-by":"crossref","first-page":"100271.","DOI":"10.1016\/j.lansea.2023.100271","article-title":"Hypertension treatment cascade among men and women of reproductive age group in India: analysis of National Family Health Survey-5 (2019\u20132021).","volume":"23:","author":"Guthi","year":"2023;","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"key20260915055752_B7","doi-asserted-by":"crossref","first-page":"274\u2013","DOI":"10.1016\/j.ijcard.2017.09.182","article-title":"Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status: an analysis from the High-Risk Myocardial Infarction Database Initiative.","volume":"249:","author":"Agewall","year":"2017;","journal-title":"Int J Cardiol"},{"issue":"(7\u20138):","key":"key20260915055752_B8","doi-asserted-by":"crossref","first-page":"637\u2013","DOI":"10.1081\/CEH-200031959","article-title":"Elevated heart rate: a major risk factor for cardiovascular disease.","volume":"26","author":"Palatini","year":"2004;","journal-title":"Clin Exp Hypertens"},{"key":"key20260915055752_B9","doi-asserted-by":"crossref","first-page":"874.","DOI":"10.3389\/fphar.2017.00874","article-title":"If channel as an emerging therapeutic target for cardiovascular diseases: a review of current evidence and controversies.","volume":"8:","author":"Mengesha","year":"2017;","journal-title":"Front Pharmacol"},{"issue":"(1):","key":"key20260915055752_B10","doi-asserted-by":"crossref","first-page":"6\u2013","DOI":"10.1016\/j.ihj.2023.12.009","article-title":"Comparison of Indian clinical practice guidelines for the management of hypertension with the World Health Organization, International Society of Hypertension, American, and European guidelines.","volume":"76","author":"Satheesh","year":"2024;","journal-title":"Indian Heart J"},{"issue":"(12):","key":"key20260915055752_B11","doi-asserted-by":"crossref","first-page":"1874\u2013","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension; endorsed by the International Society of Hypertension and the European Renal Association.","volume":"41","author":"Mancia","year":"2023;","journal-title":"J Hypertens"},{"issue":"(Suppl. A):","key":"key20260915055752_B12","doi-asserted-by":"crossref","first-page":"A1\u2013","DOI":"10.1093\/eurheartj\/sup002","article-title":"Chairmen's foreword: beta-blockade across the cardiovascular continuum\u2014when and where to use?","volume":"11","author":"Willenheimer","year":"2009;","journal-title":"Eur Heart J Suppl"},{"issue":"(10):","key":"key20260915055752_B13","first-page":"844\u2013","article-title":"Role of beta-blockers in cardiovascular disease in 2019.","volume":"72","author":"Martinez-Milla","year":"2019;","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"key20260915055752_B14","unstructured":"Best Practice Advocacy Centre New Zealand. (2017). Beta-blockers for cardiovascular conditions: one size does not fit all patients. [online] Available from: https:\/\/bpac.org.nz\/2017\/beta-blockers.aspx [Last accessed May, 2024]."},{"issue":"(4):","key":"key20260915055752_B15","doi-asserted-by":"crossref","first-page":"525\u2013","DOI":"10.1517\/17425255.2014.885951","article-title":"Models for evaluating the pharmacokinetics and pharmacodynamics for \u03b2-blockers.","volume":"10","author":"H\u00f6cht","year":"2014;","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"(4):","key":"key20260915055752_B16","doi-asserted-by":"crossref","first-page":"e00496.","DOI":"10.1002\/prp2.496","article-title":"Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.","volume":"7","author":"\u00c5gesen","year":"2019;","journal-title":"Pharmacol Res Perspect"},{"key":"key20260915055752_B17","volume-title":"Beta blocker dialyzability and effectiveness in chronic hemodialysis patients [master's thesis].","author":"Tieu","year":"2016."},{"issue":"(4):","key":"key20260915055752_B18","doi-asserted-by":"crossref","first-page":"325\u2013","DOI":"10.1080\/00926239208412857","article-title":"Bisoprolol and hypertension: effects on sexual functioning in men.","volume":"18","author":"Broekman","year":"1992;","journal-title":"J Sex Marital Ther"},{"issue":"(5):","key":"key20260915055752_B19","doi-asserted-by":"crossref","first-page":"173.","DOI":"10.31083\/j.rcm2305173","article-title":"\u03b2-Blockers and erectile dysfunction in heart failure: between myth and reality.","volume":"23","author":"Corradetti","year":"2022;","journal-title":"Rev Cardiovasc Med"},{"key":"key20260915055752_B20","doi-asserted-by":"crossref","first-page":"69\u2013","DOI":"10.1016\/j.ejim.2022.06.013","article-title":"Nebivolol protects erectile functions compared to metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: a prospective, randomized, cross-over, clinical trial.","volume":"103:","author":"Gungor","year":"2022;","journal-title":"Eur J Intern Med"},{"issue":"(4):","key":"key20260915055752_B21","doi-asserted-by":"crossref","first-page":"987\u2013","DOI":"10.1681\/ASN.2014040324","article-title":"\u03b2-Blocker dialyzability and mortality in older patients receiving hemodialysis.","volume":"26","author":"Weir","year":"2015;","journal-title":"J Am Soc Nephrol"},{"issue":"(4):","key":"key20260915055752_B22","doi-asserted-by":"crossref","first-page":"506\u2013","DOI":"10.1111\/hdi.12783","article-title":"Beta-blocker practice patterns in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis.","volume":"23","author":"Lee","year":"2019;","journal-title":"Hemodial Int"},{"issue":"(12):","key":"key20260915055752_B23","doi-asserted-by":"crossref","first-page":"1349\u2013","DOI":"10.1016\/S0895-7061(97)00320-8","article-title":"Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.","volume":"10","author":"Dominguez","year":"1997;","journal-title":"Am J Hypertens"},{"issue":"(2):","key":"key20260915055752_B24","first-page":"1\u2013","article-title":"Effect of beta-blockers on insulin resistance in patients with hypertension and metabolic syndrome after 6 months of treatment.","volume":"4","author":"Sirenko","year":"2017;","journal-title":"J Endocrinol Diab"},{"issue":"(2):","key":"key20260915055752_B25","first-page":"726.","article-title":"Carvedilol can replace insulin in the treatment of type 2 diabetes mellitus.","volume":"8","author":"Ahmad","year":"2017;","journal-title":"J Diabetes Metab"},{"issue":"(1):","key":"key20260915055752_B26","doi-asserted-by":"crossref","first-page":"1763\u2013","DOI":"10.3182\/20110828-6-IT-1002.01729","article-title":"Impact of metoprolol on insulin sensitivity in the ICU.","volume":"44","author":"Pretty","year":"2011;","journal-title":"IFAC Proc Vol"},{"issue":"(1):","key":"key20260915055752_B27","first-page":"ACPT-1017.","article-title":"Effects of nebivolol treatment on glucose and lipids metabolism.","volume":"2","author":"Lima","year":"2021;","journal-title":"Ann Clin Pharmacol Toxicol"},{"issue":"(Suppl. 1):","key":"key20260915055752_B28","doi-asserted-by":"crossref","first-page":"ehab724.2363.","DOI":"10.1093\/eurheartj\/ehab724.2363","article-title":"Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials.","volume":"42","author":"Jadhav","year":"2021;","journal-title":"Eur Heart J"},{"issue":"(3):","key":"key20260915055752_B29","first-page":"e000683.","article-title":"Efficacy and tolerability of a \u03b21-selective \u03b2-blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.","volume":"2","author":"Marya","year":"2012;","journal-title":"BMJ Open"},{"issue":"(1):","key":"key20260915055752_B30","doi-asserted-by":"crossref","first-page":"79\u2013","DOI":"10.1038\/hr.2016.101","article-title":"Comparison of bisoprolol to a metoprolol CR\/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.","volume":"40","author":"Yang","year":"2017;","journal-title":"Hypertens Res"},{"issue":"(Suppl. 1):","key":"key20260915055752_B31","first-page":"AP111.","article-title":"Abstract P111: comparative efficacy of bisoprolol compared to other selective beta-1 blockers in patients with hypertension\u2014a systematic review and meta-analysis of observational studies.","volume":"78","author":"Jadhav","year":"2021;","journal-title":"Hypertension"},{"issue":"(7):","key":"key20260915055752_B32","doi-asserted-by":"crossref","first-page":"939\u2013","DOI":"10.1080\/03007995.2023.2223915","article-title":"Efficacy and safety of bisoprolol 5 mg plus amlodipine 5 mg in patients with hypertension uncontrolled on monotherapy with 5 mg of amlodipine: a phase III multicenter, randomized, double-blind, placebo-controlled clinical trial\u2014the AMCOR study.","volume":"39","author":"J\u0119drusik","year":"2023;","journal-title":"Curr Med Res Opin"},{"issue":"(2):","key":"key20260915055752_B33","doi-asserted-by":"crossref","first-page":"182\u2013","DOI":"10.1002\/j.1552-4604.1995.tb05009.x","article-title":"First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension.","volume":"35","author":"Frishman","year":"1995;","journal-title":"J Clin Pharmacol"},{"issue":"(1):","key":"key20260915055752_B34","first-page":"113.","article-title":"Expert opinion on the use of bisoprolol-telmisartan combination in Indian patients with hypertension.","volume":"7","author":"Manjula","year":"2024;","journal-title":"Indian J Cardio Biol Clin Sci"},{"key":"key20260915055752_B35","doi-asserted-by":"crossref","first-page":"106\u2013","DOI":"10.1016\/j.phrs.2018.10.031","article-title":"Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study.","volume":"139:","author":"Sabid\u00f3","year":"2019;","journal-title":"Pharmacol Res"},{"issue":"(Suppl. 5):","key":"key20260915055752_B36","doi-asserted-by":"crossref","first-page":"S208\u2013","DOI":"10.1097\/00005344-199006165-00038","article-title":"Bisoprolol in the treatment of chronic stable angina pectoris.","volume":"16","author":"Terol","year":"1990;","journal-title":"J Cardiovasc Pharmacol"},{"issue":"(1):","key":"key20260915055752_B37","doi-asserted-by":"crossref","first-page":"231\u2013","DOI":"10.1016\/0735-1097(94)00345-Q","article-title":"Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine.","volume":"25","author":"von Arnim","year":"1995;","journal-title":"J Am Coll Cardiol"},{"key":"key20260915055752_B38","first-page":"3098726.","article-title":"The efficacy and safety of bisoprolol in the treatment of myocardial infarction with cardiac insufficiency.","volume":"2022:","author":"Wang","year":"2022;","journal-title":"Comput Math Methods Med"},{"issue":"(1):","key":"key20260915055752_B39","doi-asserted-by":"crossref","first-page":"105\u2013","DOI":"10.1016\/j.ihj.2017.11.015","article-title":"Management protocols for chronic heart failure in India.","volume":"70","author":"Mishra","year":"2018;","journal-title":"Indian Heart J"},{"issue":"(15):","key":"key20260915055752_B40","doi-asserted-by":"crossref","first-page":"1353\u2013","DOI":"10.1053\/euhj.2000.2555","article-title":"Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.","volume":"22","author":"Poldermans","year":"2001;","journal-title":"Eur Heart J"},{"issue":"(2):","key":"key20260915055752_B41","doi-asserted-by":"crossref","first-page":"46\u2013","DOI":"10.1136\/heartasia-2015-010675","article-title":"Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST-elevation myocardial infarction.","volume":"7","author":"Maclean","year":"2015;","journal-title":"Heart Asia"},{"key":"key20260915055752_B42","first-page":"182.","article-title":"To evaluate the \u2018real world\u2019 clinical performance of bisoprolol in post-myocardial infarction with left ventricular dysfunction: TENACITY study.","volume":"7:","author":"Sharma","year":"2022;","journal-title":"Cardiol Res Cardiovasc Med"},{"issue":"(5):","key":"key20260915055752_B43","doi-asserted-by":"crossref","first-page":"617\u2013","DOI":"10.1016\/j.pharma.2022.01.007","article-title":"Beta-blockers for the treatment of arrhythmias: bisoprolol\u2014a systematic review.","volume":"80","author":"Muresan","year":"2022;","journal-title":"Ann Pharm Fr"},{"key":"key20260915055752_B44","doi-asserted-by":"crossref","first-page":"18\u2013","DOI":"10.2174\/2589645801913010018","article-title":"Bisoprolol versus corticosteroid and bisoprolol combination for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery.","volume":"13:","author":"Mahrose","year":"2019;","journal-title":"Open Anesthesiol J"},{"issue":"(1):","key":"key20260915055752_B45","doi-asserted-by":"crossref","first-page":"50\u2013","DOI":"10.1016\/j.jjcc.2013.02.010","article-title":"Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study.","volume":"62","author":"Yamashita","year":"2013;","journal-title":"J Cardiol"},{"issue":"(2):","key":"key20260915055752_B46","doi-asserted-by":"crossref","first-page":"243\u2013","DOI":"10.1007\/s40119-024-00367-4","article-title":"Management of heart failure in a resource-limited setting: expert opinion from India.","volume":"13","author":"Jain","year":"2024;","journal-title":"Cardiol Ther"},{"issue":"(5):","key":"key20260915055752_B47","doi-asserted-by":"crossref","first-page":"1221\u2013","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.","volume":"28","author":"Malgie","year":"2023;","journal-title":"Heart Fail Rev"},{"issue":"(4):","key":"key20260915055752_B48","first-page":"431\u2013","article-title":"Bisoprolol in the treatment of chronic heart failure.","volume":"3","author":"de Groote","year":"2007;","journal-title":"Vasc Health Risk Manag"},{"issue":"(3):","key":"key20260915055752_B49","doi-asserted-by":"crossref","first-page":"127\u2013","DOI":"10.1111\/j.1527-5299.2004.03316.x","article-title":"Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure.","volume":"10","author":"Beck-da-Silva","year":"2004;","journal-title":"Congest Heart Fail"},{"issue":"(4):","key":"key20260915055752_B50","first-page":"569\u2013","article-title":"Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.","volume":"3","author":"Metra","year":"2007;","journal-title":"Ther Clin Risk Manag"},{"issue":"(9146):","key":"key20260915055752_B51","first-page":"9\u2013","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.","volume":"353","author":"CIBIS-II Investigators.","year":"1999;","journal-title":"Lancet"},{"issue":"(9):","key":"key20260915055752_B52","doi-asserted-by":"crossref","first-page":"873\u2013","DOI":"10.1016\/S0300-8932(03)76975-9","article-title":"Use of bisoprolol in heart failure: the BISOCOR observational study.","volume":"56","author":"Gonz\u00e1lez-Juanatey","year":"2003;","journal-title":"Rev Esp Cardiol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:58:05Z","timestamp":1789451885000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-9-83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.59556\/japi.74.1694"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1694","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}